title: Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
authors.forename: L
authors.initials: L
authors.lastname: Biancone
authors.forename: C
authors.initials: C
authors.lastname: Petruzziello
authors.forename: E
authors.initials: E
authors.lastname: Calabrese
authors.forename: F
authors.initials: F
authors.lastname: Zorzi
authors.forename: P
authors.initials: P
authors.lastname: Naccarato
authors.forename: S
authors.initials: S
authors.lastname: Onali
authors.forename: F
authors.initials: F
authors.lastname: Pallone
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab